ECH1 is a member of the hydratase/isomerase superfamily involved in fatty acid metabolism. It is localized to peroxisomes and/or mitochondria in different mammals. In humans, levels of ECH1 are modulated by peroxisome proliferators. As the name implies, ECH1 catalyzes the isomerization of cis ?3,5, double bonds in unsaturated acyl-CoAs to yield trans ?2,4-dienoyl CoAs. These are substrates for ?2,4-dienoyl CoA reductase which produces trans ?3 enoyl CoA. This intermediate can then be further transformed by ?3, ?2 - enoyl CoA isomerase to finally yield the trans-2 double bond configured fatty acyl CoA, which can be then directed into the ß-oxidation pathway. Expression of ECH1 is highest in metabolically active tissues such as heart, skeletal muscle, central nervous system, liver and kidney. Recent studies show that it is down regulated in gastric carcinoma and CLL.
Product was previously marketed under the MitoSciences sub-brand.
Immunocytochemistry image of ab110294 stained human HDFn cells. The cells were paraformaldehyde fixed (4%, 20 min) and Triton X-100 permeabilized (0.1%, 15min). The cells were incubated with the antibody (9D11AF3, 4 µg/ml) for 2h at room temperature or over night at 4°C. The secondary antibody was (green) AlexaFluor® 488 goat anti-mouse IgG (H+L) used at a 1/1000 dilution for 1h. 10% Goat serum was used as the blocking agent for all blocking steps. DAPI was used to stain the cell nuclei (blue). Target protein locates mainly in the mitochondria.
Anti-ECH1 antibody [9D11AF3] (ab110294)参考文献
has not yet been referenced specifically in any publications.